Elranatamab as Maintenance Therapy
Phase II Study of Elranatamab as Maintenance Therapy Post Ciltacabtagene-autoleucel(Cilta-cel) in Patients With Clinical High Risk Relapsed Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 39 patients (estimated)
- Sponsors
- Moffitt Cancer Center
- Collaborators
- Pfizer
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), High Risk, Maintenance, Post-CAR T
- Trial Type
- Treatment
- Last Update
- 6 hours ago
- SparkCures ID
- 2110
- NCT Identifier
- NCT06947083
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.